The incidence of HER2 amplification and/or protein overexpression ranges from 1% to 6% in the unselected population32–34, which is lower than that in patients with breast cancer (~25%) or gastric cancer (13–22%)35,36. Here, ERBB2 is linked to gastric cancer.